<DOC>
	<DOCNO>NCT00545597</DOCNO>
	<brief_summary>Study use Lorenzo 's oil adult adrenomyeloneuropathy , adult form Lorenzo 's oil .</brief_summary>
	<brief_title>A Phase III Trial Lorenzo 's Oil Adrenomyeloneuropathy</brief_title>
	<detailed_description>This double-masked placebo control study glyceryl trioleate-glyceryl trierucate ( Lorenzo 's Oil ( LO ) ) therapy adrenomyeloneuropathy ( AMN ) , adult form X-linked adrenoleukodystrophy ( X-ALD ) . AMN slowly progressive distal axonopathy involves long tract spinal cord differs rapidly progressive inflammatory cerebral form commonly affect boys adolescent . All form X-ALD associate abnormal accumulation long chain fatty acid ( VLCFA ) plasma tissue . The oral administration LO normalize plasma VLCFA level within 4 week . While previous therapeutic trial LO therapy patient cerebral form X-ALD disappointing , recent study suggest beneficial two type X-ALD : 1 ) preventive neurological involvement asymptomatic boy ; 2 ) AMN , appear slow rate progression . None previous study control , conduct first placebo-controlled trial . The 4-year study include 120 men AMN evidence cerebral involvement , 120 woman heterozygous X-ALD AMN-like syndrome . The rate progression compare LO placebo group use Kurtzke EDSS score primary outcome variety secondary outcome . Adrenomyeloneuropathy affect 1 40,000 men 1 30,000 woman . It progressive disorder lead inability walk severe deficit . This study provide definitive information whether Lorenzo 's Oil therapy slow progression .</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>Males female age 18 year old diagnosis XALD confirm VLCFA assay and/or mutation analysis . Clinical evidence spinal cord involvement EDSS score 1 6.5 . Patients EDSS score 6.5 severely affected retain capacity walk 20 meter aid walker , crutch , two cane . Either normal brain MRI , type 3 pattern MRI abnormality abnormality consider represent centripetal extension distal axonopathy . Adrenal function assess measurement plasma ACTH appropriate steroid replacement adrenal insufficiency present . Kurtzke EDSS score &gt; 6.5 . Cognitive behavioral abnormality impair capacity give inform consent carry procedure form part protocol . Current use , use within 3 month , Lorenzo 's oil therapy may alter course XALD . Bone marrow transplant permanent exclusion criterion . Contraindications MRI procedure subject paramagnetic material body , aneurysm clip , pacemaker , intraocular metal cochlear implant . Subjects pregnant . Allergies peppermint Presence nonspecific condition may interfere clinical assessment participation protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>adrenoleukodystrophy</keyword>
	<keyword>adrenomyeloneuropathy</keyword>
</DOC>